Comparative Pharmacology
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus LIBRITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus LIBRITABS.
FLURAZEPAM HYDROCHLORIDE vs LIBRITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
None Documented
None Documented
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine